bevacizumab,sorafenib,atezolizumab
roche
['hcc', 'imbrave 150']
follow-up trial to imbrave 150 advanced/metastatic hcc #asco23 #asco2023 
GI Radiation Oncologist | Associate PD @MayoRadOnc @MayoClinic | Passions for #PatientCare, #MedEd, QoL, #PublicHealth, and #ClinicalTrials | Views are my own